Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Novexel

Request full access

Pharmaceutical company that engages in the discovery and development of antibacterial and antifungal agents to treat bacterial

Romainville, FranceFounded 2004Biotech & Life Sciences

About Novexel

Novexel operated as a specialty pharmaceutical firm with a clear focus on addressing the global challenge of microbial drug resistance. The company was established in December 2004 as an independent spin-out from the anti-infectives division of sanofi-aventis, inheriting a substantial portfolio of anti-infective research programs. Based in Romainville, France, Novexel concentrated its efforts on the discovery and clinical development of novel antibiotic and antifungal agents designed to combat infections caused by drug-resistant bacteria.

The company's business model was centered on advancing its pipeline of drug candidates through various clinical trial phases to prove their safety and efficacy. Its primary clients were large pharmaceutical corporations seeking to bolster their anti-infective portfolios. Novexel's strategy involved forming strategic partnerships and licensing agreements to co-develop and commercialize its products. A key collaboration was with Forest Laboratories for the development of NXL104 in North America. Revenue was generated through these partnerships and the ultimate goal of acquisition by a larger pharmaceutical entity. This culminated in March 2010 when AstraZeneca acquired Novexel for a total potential consideration of up to $505 million. The acquisition provided AstraZeneca with Novexel's promising pipeline, aiming to meet the high unmet need for new treatments against serious hospital infections.

Novexel's product pipeline included several key candidates. NXL104 was a novel injectable beta-lactamase inhibitor developed to be combined with existing cephalosporin antibiotics, like ceftazidime, to overcome bacterial resistance. This combination, CAZ-104, was in Phase II trials for complicated intra-abdominal and urinary tract infections. Another significant asset was NXL103, an oral streptogramin antibiotic, which had shown positive Phase II results for treating community-acquired pneumonia and was being trialed for acute bacterial skin infections. The company also had preclinical programs, including NXL105, an anti-Pseudomonal antibiotic, and NXL201, an antifungal agent. Novexel's core value proposition was its specialized research in overcoming antibiotic resistance mechanisms, a critical area in healthcare.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
1
Open positions
None listed
Dealroom signal
59.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Developer Tools, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Dec 2009 $0 — AstraZeneca —
SERIES BOther financing Jan 2007 $65M $260M Andera Partners —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Novexel website traffic

Latest recorded traffic for Novexel is 0 monthly website visits. Novexel's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Novexel in the Romainville ecosystem

Live from Dealroom

The Novexel office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Andera Partners

Series B and later4 investors entered at this stage

Other known investors1 additional known investor

  • AstraZeneca
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇫🇷 France · Romainville HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Novexel on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Novexel’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.